HIFU May Be Feasible Option for Low-Risk Prostate Cancer
Jpn J Clin Oncol. 2008;38:192-199
Focal therapy with high-intensity focused ultrasound (HIFU) of localized prostate cancer provides immediate cancer control, comparable to that of other treatment modalities, according to Japanese researchers.
A team at the Teikyo University School of Medicine in
The two-year disease-free survival (DFS) rates in patients at low, intermediate, and high risk were 85.9%, 50.9%, and 0%. After 12 months, 81.6% were biopsy negative; 84.4% in patients who received whole therapy and 76.5% in those who received focal therapy. The two-year biochemical DFS rates for low and intermediate risk patients were 90.9% and 49.9%, respectively, for the whole therapy group and 83.3% and 53.6% for the focal therapy group.
In patients who did not receive neo-adjuvant androgen deprivation, serum testosterone levels decreased continuously in patients who received whole therapy, but did not change in patients treated with focal therapy.